Compares clotting and platelet activity in adults with sickle cell SS or SC
Compares clotting and platelet activity in adults with SS or SC sickle cell disease.
Plain-language title generated from the registry record
Registry title: Comparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS or SC Genotype (DrepAgreg)
Key facts
- Where
- Les Abymes, GuadeloupeSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with sickle cell disease of the SS or SC type who are in a steady state and followed at one of two named sickle cell centres.
- Age
- Older than 18 years
- Sex
- All sexes
- Disease stage
- Sickle cell disease of the SS or SC type, confirmed by electrophoresis or HPLC. Clinically in a steady state: no complication in the last month.
- Earlier treatment
- No blood transfusion in the last three months.
- Biomarker or test result
- SS or SC sickle cell genotype.
Main reasons for not taking part
- Younger than 18 years
- Sickle cell disease other than SS or SC
- Blood transfusion or bleeding therapy for less than three months
- Not affiliated with national social security
- Pregnant or breastfeeding
Read by machine on 13 November 2026.
Where in Guadeloupe
- CHU de la GuadeloupeLes Abymes, GuadeloupeContact: mélanie petapermalNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centre Hospitalier Universitaire de la Guadeloupe
- Trial code
- NCT07852442
- Record updated
- 1 October 2026
- Original description
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crises called vaso-occlusive crises (VOC) and chronic inflammation. Activated platelets from SCD patients contribute to both chronic inflammation and painful VOC. Individuals with the HbSC genotype experience anemia and less severe clinical manifestations than those with the HbSS genotype; however, they are at higher risk of venous thromboembolic events, particularly pulmonary embolism.Read full original descriptionShow less
Comparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS or SC Genotype
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crises called vaso-occlusive crises (VOC) and chronic inflammation. Activated platelets from SCD patients contribute to both chronic inflammation and painful VOC. Individuals with the HbSC genotype experience anemia and less severe clinical manifestations than those with the HbSS genotype; however, they are at higher risk of venous thromboembolic events, particularly pulmonary embolism.
This study aims to investigate whether sickle cell patients exhibit different thrombin generation profiles as well as distinct platelet activation and aggregation profiles, depending on their SS or SC genotype.
Inclusion: SCD patients with SS or SC; diagnosis of SCD performed by electrophoresis or high-performance liquid chromatography (HPLC) in a reference laboratory for hemoglobinopathies; patients older than 18 years at inclusion; clinically in a steady state at inclusion (no complication in the last month and no transfusion in the three last months); patient followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe à Pitre) or at the Adult Rare Diseases Reference Center "Sickle Cell Disease / Major Sickle Cell Syndromes" of the Avicenne hospital in Bobigny; patients who will provide written informed consent in accordance with the Declaration of Helsinki; patients affiliated with national social security.
Exclusion: patients who have received transfusion therapy or on bleeding therapy for less than three months; patients younger than 18 years old; patients with hemoglobinopathy other than SS and SC SCD; patients no affiliated with national social security; pregnant or breastfeeding patients.